Rising interest in oncolytic viruses as well as gene and immunotherapeutics for fighting cancer, metabolic, neurological and other genetically defined diseases leads to an increasing demand for special CDMO capabilites. Our almost 100-year tradition in development and manufacturing of vaccines and biopharmaceuticals and our particular expertise with live agents and proteins motivates and obliges us to reinforce our process development and integral manufacturing services in the fields of drug substance, drug product and packaging of oncolytic viruses and viral vectors for clinical phases to commercial supply.

IDT Biologika's extensive know how in different manufacturing platforms and the large and small scale commercial BSL 2 manufacturing facilities meeting FDA standards make IDT Biologika an attractive partner for contract manufacturing.